游离三碘甲状腺原氨酸水平与冠心病及其严重程度的关系

摘要/Abstract

摘要： 目的探讨游离三碘甲状腺原氨酸（FT3）水平与冠心病（CHD）及其严重程度的关系。方法选取2020年2月至2021年2月在我院行冠状动脉造影术的171名患者。依据冠状动脉造影术结果,将患者分为对照组（74名）与CHD组（97名）并计算CHD组患者的Gensini评分,比较两组间血液学指标及FT3水平并分析FT3水平与Gensini评分的相关性。结果 CHD组患者吸烟史、高血压、糖尿病的例数均高于对照组,且差异具有统计学意义（P<0.05）;CHD组患者的低密度脂蛋白（LDL）水平高于对照组、FT3水平低于对照组,且差异具有统计学意义（P<0.05）;多因素Logistic回归显示糖尿病（OR=2.623,P=0.039）、高血压（OR=2.623,P=0.039）、LDL（OR=2.623,P=0.039）及FT3（OR=2.623,P=0.039）均是CHD发病独立危险因子;Pearson相关性分析显示,FT3水平与Gensini评分呈负相关（r=-0.255,P=0.012）。结论低FT3可作为CHD的一项独立危险因素;FT3水平与Gensini评分成负相关,FT3水平越低,CHD的病情越严重。

伊鑫, 高腾, 刘强, 胡松林, 闫杰. 游离三碘甲状腺原氨酸水平与冠心病及其严重程度的关系[J]. 心血管病防治知识, 2022, 12(12): 26-29.

参考文献

[1] Gao H,Han J,Li G,et al.Effects of rosuvastatin combined with clopidogrel bisulfate on blood lipids,cardiac function and inflammatory factor levels in elderly patients with coronary heart disease[J]. Am J Transl Res,2022, 14(2):1297-1304.
[2] Chang J G.PLAC Test for Lp-PLA2 Activity to Predict Coronary Heart Disease[J]. Am Fam Physician, 2020, 101(1):44-46.
[3] 熊青峰, 马小静. 冠状动脉CT血管造影狭窄评分诊断缺血相关性病变的临床价值[J]. 实用放射学杂志, 2020, 36(10):1575-1579.
[4] Yu N, Wang L, Zeng Y, et al.The Association of Thyroid Hormones with Coronary Atherosclerotic Severity in Euthyroid Patients[J]. Horm Metab Res. 2022, 54(1):12-19.
[5] 韩秀, 田雨灵, 杜媛,等. Cys-C、FT3及Apo-A与冠心病严重程度的相关性[J]. 现代生物医学进展, 2019, 19(21):4092-4097.
[6] Chen Y, Wu X, Wu R, et a1. Changes in profile of lipids and adipokines in patients with newly diagnosed hypothyroidism and hyperthyroidism[J]. Sci Rep, 2016, 6(1):26174.
[7] Ichiki T.Thyroid Hormone and Vascular Remodeling[J]. Atheroscler Thromb. 2016, 23(3):266-275.
[8] Verbovaia N I, Kapralova I Y, Verbovoi A F.The 1evels of resistin and other adipokines in patients with hypothyroidism[J]. Ter Arkh, 2014, 86(10):33-35.
[9] 叶丽丽, 阮云军, 邱健,等. 血脂异常患者HDL-C、甲状腺激素与冠心病的相关性分析[J]. 中国医药导刊, 2017, 19(12):4.
[10] Aydin M U, Aygul N, Altunkeser B B, et al.Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction[J]. Atherosclerosis, 2015, 239(2):439-443.
[11] Dayami, Lopez, Jose F, et al, Ness.Activation of the hepatic LDL receptor promoter by thyroid hormone[J]. Biochim Biophys Acta, 2007, 1771(9):1216-25.
[12] Goldberg I J, Huang L S, Huggins L A, et al.Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated Pathway[J]. Endocrinology, 2012, 153(11):5143-5149.
[13] Liu YY, Brent G A.Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation[J]. Trends Endocrinol Metab, 2010, 21(3):166-173.
[14] Sofogianni A, Alkagiet S, Tziomalos K.Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease[J]. Curr Pharm Des. 2018, 24(3):291-296.
[15] Tseng F Y,Lin W Y,Lin C C, et al.Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascularmortality in adults[J]. J Am Coll Cardiol, 2012, 60(8) 730-737.
[16] 张宇云, 陈小紫. 甲状腺功能正常人群甲状腺激素水平与冠心病的相关性研究[J]. 实用心脑肺血管病杂志, 2015, 23(9):22-24.
[17] Vijayvergiya R,Kapoor D,Aggarwal A,et al.Analysis of traditional and emerging risk factors in premenopauSAPl women with coronary artery disease: a pilot scale study from North India[J]. Mol Cell Biochem, 2017, 432(1-2):67-78.
[18] 于楠, 高莹, 龚艳君, 等. 甲状腺功能与冠心病及其严重程度的相关性研究[J]. 中国介入心脏病学杂志. 2017, 25(12):671-676.
[19] Jabbar A, Pingitore A, Pearce SH, et al.Thyroid hormones and cardiovascular disease[J].Nat Rev Cardiol. 2017, 14(1):39-55.
[20] 陈霞霞, 韩敏, 高颖, 等. 低T3综合征与冠心病患者冠脉病变程度的相关性研究[J]. 新疆医科大学学报. 2019, 42(3):297-300.
[21] Lazzeri C, Sori A, Picariello C, et al. Nonthyroidalillness syndrome in ST-elevation myocardial infarction treated with mechanical revascuIarization[J]. Int J Cardiol, 2012, 158(1):103-104.